Upregulation and activation of δ‑opioid receptors promotes the progression of human breast cancer

Wei,Yang‑Chao; Zhang,Bin; Li,Xuan; Liu,Xiao‑Meng; Zhang,Jing; Lei,Biao; Li,Bo; Zhai,Run; Chen,Qian; Li,Yang

doi:10.3892/or.2016.5109

Upregulation and activation of δ‑opioid receptors promotes the progression of human breast cancer

Authors:
- Yang‑Chao Wei
- Bin Zhang
- Xuan Li
- Xiao‑Meng Liu
- Jing Zhang
- Biao Lei
- Bo Li
- Run Zhai
- Qian Chen
- Yang Li
View Affiliations

Affiliations: Department of Medical Oncology, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541001, P.R. China, Department of Breast and Thyroid Surgery, The First Hospital of Jining, Jining, Shandong 272011, P.R. China, Department of Hepatobiliary Surgery, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541001, P.R. China, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong University, Jinan, Shandong 250017, P.R. China
Published online on: September 19, 2016 https://doi.org/10.3892/or.2016.5109
Pages: 2579-2586

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

δ‑opioid receptor (DOR) belongs to the family of G protein‑coupled receptors (GPCRs). Numerous studies have shown that DOR is widely distributed in human peripheral tissues and is closely related to the development and progression of certain malignant tumours. However, there is controversy in the literature regarding whether DOR has an impact on the development and progression of human breast cancer. The present study comprehensively elaborates on the biological functions of DOR by determining the distribution of DOR expression in breast cancer tissues and cells and by further verifying the effects of DOR on breast cancer progression. DOR was found to be highly expressed in human breast cancer tissues and cells. In addition, the high expression level of DOR positively correlated with tumour grade and clinical stage and negatively correlated with breast cancer metastasis and prognosis. Upregulating and activating DOR promoted the proliferation of human breast cancer cells in a concentration‑dependent manner within a specific concentration range, whereas downregulating or inhibiting DOR activation significantly suppressed cell proliferation. The majority of tumour cells were arrested in G1 phase, and some cells exhibited apoptosis. DOR upregulation and activation induced protein kinase C (PKC) activation, resulting in increased phosphorylation levels of extracellular signal‑regulated kinases (ERKs). After inhibition of the PKC/ERK signalling pathway, the effects of DOR on breast cancer were significantly attenuated in vivo and in vitro. In summary, DOR is highly expressed in breast cancer and is closely related to its progression. These results suggest that DOR may serve as a potential biomarker for the early diagnosis of breast cancer and may be a viable molecular target for therapeutic intervention.

View Figures

View References

1	McPherson K, Steel CM and Dixon JM: ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ. 321:624–628. 2000. View Article : Google Scholar : PubMed/NCBI
2	Benson JR and Jatoi I: The global breast cancer burden. Future Oncol. 8:697–702. 2012. View Article : Google Scholar : PubMed/NCBI
3	Anderson WF, Katki HA and Rosenberg PS: Incidence of breast cancer in the United States: Current and future trends. J Natl Cancer Inst. 103:1397–1402. 2011. View Article : Google Scholar : PubMed/NCBI
4	Kieffer BL, Befort K, Gaveriaux-Ruff C and Hirth CG: The delta-opioid receptor: Isolation of a cDNA by expression cloning and pharmacological characterization. Proc Natl Acad Sci USA. 89:12048–12052. 1992. View Article : Google Scholar : PubMed/NCBI
5	Evans CJ, Keith DE Jr, Morrison H, Magendzo K and Edwards RH: Cloning of a delta opioid receptor by functional expression. Science. 258:1952–1955. 1992. View Article : Google Scholar : PubMed/NCBI
6	Bzdega T, Chin H, Kim H, Jung HH, Kozak CA and Klee WA: Regional expression and chromosomal localization of the delta opiate receptor gene. Proc Natl Acad Sci USA. 90:9305–9309. 1993. View Article : Google Scholar : PubMed/NCBI
7	Simonin F, Befort K, Gavériaux-Ruff C, Matthes H, Nappey V, Lannes B, Micheletti G and Kieffer B: The human delta-opioid receptor: Genomic organization, cDNA cloning, functional expression, and distribution in human brain. Mol Pharmacol. 46:1015–1021. 1994.PubMed/NCBI
8	Howells RD, Kilpatrick DL, Bailey LC, Noe M and Udenfriend S: Proenkephalin mRNA in rat heart. Proc Natl Acad Sci USA. 83:1960–1963. 1986. View Article : Google Scholar : PubMed/NCBI
9	Fickel J, Bagnol D, Watson SJ and Akil H: Opioid receptor expression in the rat gastrointestinal tract: A quantitative study with comparison to the brain. Brain Res Mol Brain Res. 46:1–8. 1997. View Article : Google Scholar : PubMed/NCBI
10	Neidle A, Manigault I and Wajda IJ: Distribution of opiate-like substances in rat tissues. Neurochem Res. 4:399–410. 1979. View Article : Google Scholar : PubMed/NCBI
11	Wittert G, Hope P and Pyle D: Tissue distribution of opioid receptor gene expression in the rat. Biochem Biophys Res Commun. 218:877–881. 1996. View Article : Google Scholar : PubMed/NCBI
12	Radulović J and Janković BD: Opposing activities of brain opioid receptors in the regulation of humoral and cell-mediated immune responses in the rat. Brain Res. 661:189–195. 1994. View Article : Google Scholar
13	Kilpatrick DL, Howells RD, Noe M, Bailey LC and Udenfriend S: Expression of preproenkephalin-like mRNA and its peptide products in mammalian testis and ovary. Proc Natl Acad Sci USA. 82:7467–7469. 1985. View Article : Google Scholar : PubMed/NCBI
14	Chen CL, Chang CC, Krieger DT and Bardin CW: Expression and regulation of proopiomelanocortin-like gene in the ovary and placenta: Comparison with the testis. Endocrinology. 118:2382–2389. 1986. View Article : Google Scholar : PubMed/NCBI
15	Civelli O, Douglass J, Goldstein A and Herbert E: Sequence and expression of the rat prodynorphin gene. Proc Natl Acad Sci USA. 82:4291–4295. 1985. View Article : Google Scholar : PubMed/NCBI
16	Debruyne D, Leroy A, DE Wever O, Vakaet L, Mareel M and Bracke M: Direct effects of delta opioid receptor agonists on invasion-associated activities of HCT-8/E11 colon cancer cells. Anticancer Res. 30:9–17. 2010.PubMed/NCBI
17	Kuniyasu H, Luo Y, Fujii K, Sasahira T, Moriwaka Y, Tatsumoto N, Sasaki T, Yamashita Y and Ohmori H: CD10 enhances metastasis of colorectal cancer by abrogating the anti-tumoural effect of methionine-enkephalin in the liver. Gut. 59:348–356. 2010. View Article : Google Scholar
18	Schreiber G, Campa MJ, Prabhakar S, O'Briant K, Bepler G and Patz EF Jr: Molecular characterization of the human delta opioid receptor in lung cancer. Anticancer Res. 18:1787–1792. 1998.PubMed/NCBI
19	Cieślińska A, Sienkiewicz-Szłapka E, Kostyra E, Fiedorowicz E, Snarska J, Wroński K, Tenderenda M, Jarmołowska B and Matysiewicz M: µ-Opioid receptor gene (OPRM1) polymorphism in patients with breast cancer. Tumour Biol. 36:4655–4660. 2015. View Article : Google Scholar
20	Molè D, Gentilin E, Gagliano T, Tagliati F, Bondanelli M, Pelizzo MR, Rossi M, Filieri C, Pansini G, degli Uberti EC, et al: Protein kinase C: A putative new target for the control of human medullary thyroid carcinoma cell proliferation in vitro. Endocrinology. 153:2088–2098. 2012. View Article : Google Scholar : PubMed/NCBI
21	Wickley PJ, Ding X, Murray PA and Damron DS: Propofol-induced activation of protein kinase C isoforms in adult rat ventricular myocytes. Anesthesiology. 104:970–977. 2006. View Article : Google Scholar : PubMed/NCBI
22	Saberi B, Shinohara M, Ybanez MD, Hanawa N, Gaarde WA, Kaplowitz N and Han D: Regulation of H(2)O(2)-induced necrosis by PKC and AMP-activated kinase signaling in primary cultured hepatocytes. Am J Physiol Cell Physiol. 295:C50–C63. 2008. View Article : Google Scholar : PubMed/NCBI
23	Ali AS, Ali S, El-Rayes BF, Philip PA and Sarkar FH: Exploitation of protein kinase C: A useful target for cancer therapy. Cancer Treat Rev. 35:1–8. 2009. View Article : Google Scholar
24	Oskoueian E, Abdullah N and Ahmad S: Phorbol esters from Jatropha meal triggered apoptosis, activated PKC-δ, caspase-3 proteins and down-regulated the proto-oncogenes in MCF-7 and HeLa cancer cell lines. Molecules. 17:10816–10830. 2012. View Article : Google Scholar : PubMed/NCBI
25	Li Z, Wang N, Fang J, Huang J, Tian F, Li C and Xie F: Role of PKC-ERK signaling in tamoxifen-induced apoptosis and tamoxifen resistance in human breast cancer cells. Oncol Rep. 27:1879–1886. 2012.PubMed/NCBI
26	Zhu M, Li M, Yang F, Ou X, Ren Q, Gao H, Zhu C and Guo J: Mitochondrial ERK plays a key role in δ-opioid receptor neuroprotection against acute mitochondrial dysfunction. Neurochem Int. 59:739–748. 2011. View Article : Google Scholar : PubMed/NCBI
27	Sancho P, Galeano E, Estañ MC, Gañán-Gómez I, Boyano-Adánez MC and García-Pérez AI: Raf/MEK/ERK signaling inhibition enhances the ability of dequalinium to induce apoptosis in the human leukemic cell line K562. Exp Biol Med (Maywood). 237:933–942. 2012. View Article : Google Scholar
28	Zhao M, Wang HX, Yang J, Su YH, Su RJ and Wong TM: delta-Opioid receptor stimulation enhances the growth of neonatal rat ventricular myocytes via the extracellular signal-regulated kinase pathway. Clin Exp Pharmacol Physiol. 35:97–102. 2008. View Article : Google Scholar
29	Hayashi T, Tsao LI and Su TP: Antiapoptotic and cytotoxic properties of delta opioid peptide [D-Ala(2),D-Leu(5)] enkephalin in PC12 cells. Synapse. 43:86–94. 2002. View Article : Google Scholar
30	Bilecki W, Zapart G, Ligeza A, Wawrzczak-Bargiela A, Urbański MJ and Przewłocki R: Regulation of the extracellular signal-regulated kinases following acute and chronic opioid treatment. Cell Mol Life Sci. 62:2369–2375. 2005. View Article : Google Scholar : PubMed/NCBI
31	American Cancer Society: Cancer facts and figures. 2006, http://www.cancer.org/downloads/STT/CAFF2006PWSecured.pdf Accessed February 7, 2007.
32	Kuhl CK, Schrading S, Leutner CC, Morakkabati-Spitz N, Wardelmann E, Fimmers R, Kuhn W and Schild HH: Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol. 23:8469–8476. 2005. View Article : Google Scholar : PubMed/NCBI
33	Brownstein MJ: A brief history of opiates, opioid peptides, and opioid receptors. Proc Natl Acad Sci USA. 90:5391–5393. 1993. View Article : Google Scholar : PubMed/NCBI
34	Al-Hasani R and Bruchas MR: Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology. 115:1363–1381. 2011.PubMed/NCBI
35	Su TP: Delta opioid peptide[D- Ala(2),D-Leu(5)]enkephalin promotes cell survival. J Biomed Sci. 7:195–199. 2000.PubMed/NCBI
36	Kim H, Lee SW, Park JS, Min JH and Kim HK: Genomic analysis of [d-Ala², d-Leu⁵] enkephalin preconditioning in cortical neuron and glial cell injury after oxygen deprivation. Brain Res. 1447:91–105. 2012. View Article : Google Scholar : PubMed/NCBI
37	Avella DM, Kimchi ET, Donahue RN, Tagaram HR, McLaughlin PJ, Zagon IS and Staveley-O'Carroll KF: The opioid growth factor-opioid growth factor receptor axis regulates cell proliferation of human hepatocellular cancer. Am J Physiol Regul Integr Comp Physiol. 298:R459–R466. 2010. View Article : Google Scholar :
38	Stewart ZA, Westfall MD and Pietenpol JA: Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol Sci. 24:139–145. 2003. View Article : Google Scholar : PubMed/NCBI
39	Allen TR, Krueger KD, Hunter WJ III and Agrawal DK: Evidence that insulin-like growth factor-1 requires protein kinase C-epsilon, PI3-kinase and mitogen-activated protein kinase pathways to protect human vascular smooth muscle cells from apoptosis. Immunol Cell Biol. 83:651–667. 2005. View Article : Google Scholar : PubMed/NCBI
40	Agudo-López A, Miguel BG, Fernández I and Martínez AM: Role of protein kinase C and mitochondrial permeability transition pore in the neuroprotective effect of ceramide in ischemia-induced cell death. FEBS Lett. 585:99–103. 2011. View Article : Google Scholar
41	Peng Y, Hu Y, Feng N, Wang L and Wang X: L-3-n-butyl-phthalide alleviates hydrogen peroxide-induced apoptosis by PKC pathway in human neuroblastoma SK-N-SH cells. Naunyn Schmiedebergs Arch Pharmacol. 383:91–99. 2011. View Article : Google Scholar
42	Heiss A, Ammer H and Eisinger DA: delta-Opioid receptor-stimulated Akt signaling in neuroblastoma × glioma (NG108-15) hybrid cells involves receptor tyrosine kinase-mediated PI3K activation. Exp Cell Res. 315:2115–2125. 2009. View Article : Google Scholar : PubMed/NCBI
43	Huang D, Ding Y, Luo WM, Bender S, Qian CN, Kort E, Zhang ZF, VandenBeldt K, Duesbery NS, Resau JH, et al: Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. Cancer Res. 68:81–88. 2008. View Article : Google Scholar : PubMed/NCBI
44	Tang B, Du J, Gao ZM, Liang R, Sun DG, Jin XL and Wang LM: DADLE suppresses the proliferation of human liver cancer HepG2 cells by activation of PKC pathway and elevates the sensitivity to cis-diammine dichloridoplatium. Zhonghua Zhong Liu Za Zhi. 34:425–429. 2012.In Chinese. PubMed/NCBI